A Targeted Antibody Approach to Alpha-Gal Syndrome
Alpha-gal syndrome (AGS) presents an unusual therapeutic challenge: exposure to galactose-α-1,3-galactose (α-Gal), a carbohydrate found on mammalian glycoproteins and glycolipids, can trigger potentially life-threatening IgE-mediated reactions, yet no disease-modifying treatment is currently available.
In this study, investigators explored whether α-Gal–specific monoclonal antibodies (mAbs) could interrupt the allergic response by preventing patient IgE from engaging α-Gal–containing allergens.
An Unexpected Route to Potential AGS Therapy
Interestingly, these antibodies were not originally developed for AGS. Researchers initially analyzed samples from a malaria-exposed cohort in Mali to look for antibodies that could target α-Gal on Plasmodium falciparum sporozoites, which is the stage of the parasite that first infects humans. From 18 participants with high α-Gal antibody responses, they sorted 17,388 B cells and ultimately generated 42 fully human α-Gal–specific recombinant mAbs. The panel consisted predominantly of IgM antibodies (73.8%), followed by IgA (16.7%) and IgG (9.5%), with frequent use of the IGHV3 gene family.
However, nearly all of the α-Gal–specific mAbs showed little to modest binding to P. falciparum sporozoites, which prompted investigators to explore whether they might instead recognize clinically relevant AGS allergens.
As a first step, the researchers tested the mAbs against three α-Gal–containing AGS allergens that showed strong IgE reactivity in serum from patients with AGS: angiotensin-I-converting enzyme (ACE), aminopeptidase-N (AP-N), and cetuximab. Thirteen of the 42 mAbs bound the AGS allergens ACE, AP-N, and cetuximab with variable binding affinities.
Of these 13 mAbs, two stood out for their ability to block patient IgE from binding the allergens:
- AG028 (as IgA₂ and IgM) inhibited serum IgE binding to ACE, AP-N, and cetuximab by approximately 60–97%.
- AG050 IgA₁ inhibited binding to ACE and AP-N by roughly 81–91%, but not cetuximab.
But blocking IgE binding doesn’t necessarily mean preventing an allergic cellular response, which is why the researchers performed an indirect basophil activation test.
Basophils are key effector cells in IgE-mediated allergy; allergen-driven cross-linking of surface-bound IgE activates these cells and promotes release of inflammatory mediators. In cells sensitized with serum from one patient, AG028 IgA2 and IgM inhibited ACE-induced basophil activation by 86.2% and 78.8%, respectively, and AP-N–induced activation by 60.1% and 68.8%. However, this effect was not reproduced with serum from a second patient, and AG050 showed little functional inhibition despite strong IgE blocking in other assays.
A Proof of Concept, with Important Questions Remaining
These findings remain preclinical and reveal substantial patient-to-patient variability. The antibodies were also isolated from malaria-exposed individuals rather than patients with AGS, and their affinities were modest compared with mAbs developed for other food allergies. The authors suggest that future work could isolate higher-affinity antibodies directly from patients with AGS or optimize promising antibodies through protein engineering.
Overall, the study provides proof of concept that α-Gal–specific mAbs can interfere with IgE binding and, under some conditions, suppress downstream basophil activation. Rather than demonstrating a treatment ready for clinical use, these experiments establish a foundation for developing more potent, broadly active antibody-based approaches to AGS.
Reference:
Cho H, Seo Y, Sohn H, et al. Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens. J Clin Invest. 2026;136(17):e192370. doi:10.1172/JCI192370
